4 月23 日公司公告宣布,AK112-306 中期分析强阳性结果,成为依沃西单抗在NSCLC 领域斩获的第2 个头对头阳性结果,标志着本品向肺癌全适应症重磅药迈进:1)将一线人群拓展至PD-L1 阴性患者;2)强化了在联用化疗、鳞癌患者中对传统PD-1 单抗的优效证据,海外一线III 期研究成功前景或更加明朗;3)参考既往Summit 在国内注册临床达终点后加速对应海外研究速度,HARMONi-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.